These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6734032)

  • 21. The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease.
    Torkaman-Boutorabi A; Shahidi GA; Choopani S; Rezvani M; Pourkosary K; Golkar M; Zarrindast MR
    Acta Neurobiol Exp (Wars); 2012; 72(3):272-82. PubMed ID: 23093014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.
    Contin M; Martinelli P; Mochi M; Riva R; Albani F; Baruzzi A
    Mov Disord; 2005 Jun; 20(6):734-9. PubMed ID: 15747357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white Americans.
    McLeod HL; Fang L; Luo X; Scott EP; Evans WE
    J Pharmacol Exp Ther; 1994 Jul; 270(1):26-9. PubMed ID: 8035323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Sovijärvi A; Kaakkola S; Gordin A; Teräväinen H
    Clin Neuropharmacol; 2001; 24(1):50-7. PubMed ID: 11290882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
    Gray R; Patel S; Ives N; Rick C; Woolley R; Muzerengi S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE;
    JAMA Neurol; 2022 Feb; 79(2):131-140. PubMed ID: 34962574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. L-DOPA biotransformation: correlations of dosage, erythrocyte catechol O-methyltransferase and platelet SULT1A3 activities with metabolic pathways in Parkinsonian patients.
    Dousa MK; Weinshilboum RM; Muenter MD; Offord KP; Decker PA; Tyce GM
    J Neural Transm (Vienna); 2003 Aug; 110(8):899-910. PubMed ID: 12898345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.
    Dos Santos EUD; da Silva IIFG; Asano AGC; Asano NMJ; De Mascena Diniz Maia M; de Souza PRE
    Mol Biol Rep; 2020 Nov; 47(11):8997-9004. PubMed ID: 33151475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COMT inhibition in the treatment of Parkinson's disease.
    Ruottinen HM; Rinne UK
    J Neurol; 1998 Nov; 245(11 Suppl 3):P25-34. PubMed ID: 9808337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erythrocyte catechol-O-methyltransferase activity in a Swedish population.
    Floderus Y; Ross SB; Wetterberg L
    Clin Genet; 1981 May; 19(5):389-92. PubMed ID: 7296928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.
    Müller T; Woitalla D; Muhlack S
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Jun; 383(6):627-33. PubMed ID: 21533995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extending levodopa action: COMT inhibition.
    Martínez-Martín P; O'Brien CF
    Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.
    Huot P; Johnston TH; Snoeren T; Koprich JB; Hill MP; Fox SH; Brotchie JM
    Eur J Neurosci; 2013 Mar; 37(5):831-8. PubMed ID: 23281915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone).
    Soares-da-Silva P; Vieira-Coelho MA; Parada A
    Pharmacol Toxicol; 2003 Jun; 92(6):272-8. PubMed ID: 12787259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.
    Stocchi F
    Expert Opin Pharmacother; 2006 Jul; 7(10):1399-407. PubMed ID: 16805724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of 3',4'-dihydroxy-2-methyl-propriophenone (U-0521) on catechol-O-methyltransferase activity and on DOPA accumulation in rat red blood cells and corpus striatum.
    Reches A; Jiang D; Fahn S
    Biochem Pharmacol; 1982 Nov; 31(21):3415-8. PubMed ID: 7150363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inheritance of low erythrocyte catechol-o-methyltransferase activity in man.
    Weinshilboum RM; Raymond FA
    Am J Hum Genet; 1977 Mar; 29(2):125-35. PubMed ID: 848488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease.
    Cheshire P; Bertram K; Ling H; O'Sullivan SS; Halliday G; McLean C; Bras J; Foltynie T; Storey E; Williams DR
    Neurodegener Dis; 2014; 13(1):24-8. PubMed ID: 24008922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment.
    Espinoza S; Manago F; Leo D; Sotnikova TD; Gainetdinov RR
    CNS Neurol Disord Drug Targets; 2012 May; 11(3):251-63. PubMed ID: 22483291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
    Rocha JF; Ferreira JJ; Falcão A; Santos A; Pinto R; Nunes T; Almeida L; Soares-da-Silva P
    Clin Pharmacol Drug Dev; 2016 May; 5(3):232-40. PubMed ID: 27163503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease.
    Chong DJ; Suchowersky O; Szumlanski C; Weinshilboum RM; Brant R; Campbell NR
    Clin Neuropharmacol; 2000; 23(3):143-8. PubMed ID: 10895397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.